Ambrisentan and Cardioversion - a phase IV clinical study of FDA data

Summary:

Cardioversion is reported as a side effect among people who take Ambrisentan (ambrisentan), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Uptravi, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Cardioversion when taking Ambrisentan. It is created by eHealthMe based on reports of 61,294 people who have side effects when taking Ambrisentan from the FDA, and is updated regularly.

What is Ambrisentan?

Ambrisentan has active ingredients of ambrisentan. eHealthMe is studying from 61,368 Ambrisentan users. Check the latest studies of Ambrisentan.

What is Cardioversion?

Cardioversion is found to be associated with 190 drugs and 345 conditions by eHealthMe. Check the latest studies of Cardioversion.

On Jul, 10, 2026

61,294 people reported to have side effects when taking Ambrisentan.
Among them, 33 people (0.05%) have Cardioversion.

Among these 33 people:

How long have people been on Ambrisentan when they have Cardioversion? *

What is the gender of people who have Cardioversion when taking Ambrisentan? *

female: 48.48 %
male: 51.52 %

What is the age of people who have Cardioversion when taking Ambrisentan? *

What are other drugs people take besides Ambrisentan? *

What are other side effects people have besides Cardioversion? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 14 people, 42.42%
Dyspnea (difficult or laboured breathing): 8 people, 24.24%
Heart Rate Increased: 7 people, 21.21%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 6 people, 18.18%
Disease Progression: 6 people, 18.18%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 6 people, 18.18%
N-Terminal Prohormone Brain Natriuretic Peptide Increased: 6 people, 18.18%
Hypotension (abnormally low blood pressure): 6 people, 18.18%
Cardiac Failure: 6 people, 18.18%
Blood Creatinine Increased: 6 people, 18.18%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 14 people, 42.42%
Constipation: 6 people, 18.18%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 15.15%
High Blood Cholesterol: 4 people, 12.12%
Disease Progression: 3 people, 9.09%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 1 person, 3.03%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 1 person, 3.03%
Fluid Overload (too much fluid in the blood): 1 person, 3.03%
Cardiac Disorder: 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Ambrisentan and have Cardioversion?

- Check whether Cardioversion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ambrisentan:

Ambrisentan (61,368 reports)

Cardioversion treatments and more:

Cardioversion (2,120 reports)

Browse all side effects of Ambrisentan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardioversion:

Cardioversion (190 drugs)

Browse all the conditions that are associated with Cardioversion:

Cardioversion (345 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Ambrisentan) and Ambrisentan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.